StonvexLoading…
StonvexStonvexStonvexCore line items from CBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $1.04M | $10.84M | $0.00 | $0.00 |
Operating Income | $-24.73M | $-152.63M | $-14.22M | $-17.19M |
Net Income | $-23.28M | $-23.30M | $-15.15M | $-17.87M |
EPS (Diluted) | Not available | Not available | $-0.04 | $-0.59 |
Total Assets | $199.13M | $240.29M | $5.99M | $35.62M |
Total Liabilities | $15.28M | $37.28M | $2.62M | $47.10M |
Cash & Equivalents | $189.16M | $213.19M | $22.43M | $34.77M |
Free Cash Flow OCF − CapEx | $-9.08M | $-72.45M | $-10.85M | $-6.27M |
Shares Outstanding | 27.57M | 27.56M | 64.53M | 1.02M |